Pharmaceutical

Chinese NMPA approves AstraZeneca’s Calquence for leukaemia

The Chinese NMPA approved for AstraZeneca’s Calquence to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma in adults.

Sep 5, 2023 - 20:00
Chinese NMPA approves AstraZeneca’s Calquence for leukaemia
The Chinese NMPA approved for AstraZeneca’s Calquence to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma in adults.
Read the original article

Tags:

Previous Article

UK MHRA approves AbbVie’s migraine prevention drug Aquipta

Next Article

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Life-extending epilepsy surgery performed less often in Black children, study finds

Life-extending epilepsy surgery performed less often in...

Dec 1, 2023

Overdose deaths during pregnancy spiked over the past few years, study says

Overdose deaths during pregnancy spiked over the past f...

Nov 23, 2023

Viatris gets grant for nasal spray method for treating ...

Apr 25, 2024